Thermo Fisher Scientific Elects New Director to Board

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has elected R. Alexandra "Alex" Keith to its board of directors. Ms. Keith's appointment brings the company's total number of board members to 13.

Alex is the CEO of Procter & Gamble's ("P&G") global Beauty business, based in Geneva, Switzerland , and sits on P&G's Global Leadership Council. In her current role, she oversees a $13 billion business with 10,000 employees around the world. Alex has spent her entire 30-year career at P&G in a variety of roles including manufacturing, logistics, communications and product innovation.

"Alex is a visionary leader and brand-builder who continuously pushes the boundaries of innovation while staying focused on results," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "She will be an asset to our board as Thermo Fisher continues to strengthen its global brand with customers around the world."

Alex was named to the Fortune Most Powerful Women International List in 2018, 2019 and 2020. She graduated with a Bachelor of Science degree in Chemical Engineering from the University of Arizona .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com

Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-elects-new-director-to-board-301178260.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

Thermo Fisher Scientific TMO Medical Device Investing

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Date:	Thursday, May 2, 2024
Time:	8:00 a.m. U.S. EDT
Webcast:	http://ir.bauschhealth.com/events-and-presentations

Investor Contact:		Media Contact:
Garen Sarafian		Kevin Wiggins
ir@bauschhealth.com		corporate.communications@bauschhealth.com
(877) 281-6642 (toll-free)		(908) 541-3785

Investor Contact:		Media Contact:

Garen Sarafian		Kevin Wiggins
ir@bauschhealth.com		corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)		(848) 541-3785

Contacts:
Sabrina Zimring	Ryan Weispfenning
Public Relations	Investor Relations
+1-720-774-3454	+1-763-505-4626

Investor Contact:
Knight Therapeutics Inc.

Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T. +598.2626.2344
F: 514.481.4116
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

Thermo Fisher Scientific Elects New Director to Board

Latest News

Latest Press Releases

Related News

TOP STOCKS